Market Cap N/A
Revenue (ttm) 2.24M
Net Income (ttm) -42.19M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 3,100
Avg Vol 14,092
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 82%
Beta N/A
Analysts Strong Sell
Price Target N/A

Company Profile

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte glo...

Industry: Biotechnology
Sector: Healthcare
Phone: 605 679 6980
Address:
777 W 41st St., Miami Beach, United States
Latest News on SABSW
No data available.